A Test of CKD IQ: 10 Questions for Primary Care Clinicians
CKD IQ Test Preview: When should you suspect kidney disease? What measure is used to define chronic kidney disease? What UACR test result indicates albuminuria? Good luck.
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of June 1, 2021
Data from the Johns Hopkins COVID-19 interactive map and the CDC on COVID-19 vaccinations, cases, and deaths in the US and on cases and deaths worldwide.
SGLT-2 Inhibitors: Mikhail Kosiborod, MD, Highlights the Journey to Pluripotency
Mikhail Kosiborod, MD, a lead investigator for clinical trials of SGLT2 inhibitors, traces the class history from antidiabetic agents to guideline-recommended multidisease treatments.
Post-bariatric Surgery Follow-up Found Inadequate, Putting Patients at Risk
UK investigators found guideline-recommended post-specialist care deficient, including low levels of nutrition monitoring and widely variable prescription of dietary supplements.
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of May 27, 2021
Primary Viewpoints Episode 9: Long COVID: A Review
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Ani Nalbandian, MD.
Pericardial Fat Increases Risk for HF, Especially HFpEF
Results of this large study also suggest women with high pericardial fat volume are at greater risk for HF than men, findings that have implications for stratifying prevention and treatment.
5 Myths that Persist about COVID-19 Vaccines
Truth: 67% of US unvaccinated adults believe or cannot judge the veracity of the 5 myths that follow. With more than half the population not fully vaccinated, there is more work to do.
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of May 26, 2021
SPRINT Trial Results Confirmed in New Analysis: Yes, Lower is Better
An analysis of final data from the landmark SPRINT trial has confirmed findings that support aggressive treatment of hypertension to reduce CV morbidity and mortality.
How to Slow CKD Progression: Treatment Essentials for Primary Care
Most patients with chronic kidney disease are treated in primary care where the primary goal is twofold: slow progression and prevent complications. Find essentials of both, here.
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of May 25, 2021
Moderna COVID-19 Vaccine Found Safe, 100% Effective in Adolescents Aged 12-17 Years
In the phase 2/3 TeenCOVE study, Moderna's mRNA-1273 demonstrated immunogenicity noninferior to that seen in the phase 3 adult study comparator group.
SARS-CoV-2 Variants: Update on CDC Classifications
The CDC defines SARS-CoV-2 variants as of interest, of concern, and of high consequence. Get a quick update on how knowledge of known variants is changing.
10 States with the Highest Percentage of Fully Vaccinated Population
Maine continues to lead the country in percentage of population fully vaccinated at 51.82%, according to CDC data. Mississippi has shifted into the 51st spot.
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of May 24, 2021
ACC.21: High- and Low-Dose Aspirin Both Effective for Patients with Established Cardiovascular Disease
ACC.21: There was no difference found between high- and low-dose aspirin in terms of effectiveness and safety in patients with established CVD, according to new research.
Updated CDC Guidance for Fully Vaccinated People: Takeaways for Primary Care
The newest CDC guidance greatly reduces situations that require use of masks, distancing, and testing but has raised many questions. Here's help to answer the ones your patients may ask.
SURPASS-4: Tirzepatide Reduces A1c, Weight vs Glargine in Patients with T2D, High CV Risk
New topline data from the global SURPASS-4 trial shows treatment with investigational agent tirzepatide led to superior reductions in A1c and body weight vs insulin glargine.
ACC.21: Finerenone Shows Potential to Delay Afib Onset in Patients with CKD, T2D
ACC.2021: A new analysis of FIDELIO-DKD found patients with chronic kidney disease and type 2 diabetes were about 30% less likely to develop atrial fibrillation vs those treated with placebo.